Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,280.00
-80.00 (-1.49%)
Last updated: Feb 26, 2026, 2:10 PM KST

Bukwang Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
29,52490,091151,22785,51782,77779,291
Short-Term Investments
188,02740,000--1,50010,300
Cash & Short-Term Investments
217,552130,091151,22785,51784,27789,591
Cash Growth
85.00%-13.98%76.84%1.47%-5.93%138.37%
Accounts Receivable
27,44923,55935,72987,95090,428103,675
Other Receivables
1,657994.311,647360.042,413309.45
Receivables
29,10624,55337,37688,31092,842103,985
Inventory
52,78141,66756,83238,60739,29451,375
Prepaid Expenses
306.8398.29166.97173.46205.7216.08
Other Current Assets
6,1707,0308,5766,1343,4763,043
Total Current Assets
305,915203,739254,179218,741220,095248,209
Property, Plant & Equipment
143,271141,481122,789123,960124,531106,298
Long-Term Investments
14,19616,77531,62635,13236,96334,189
Goodwill
406.62406.62878.73834.51828.7827.05
Other Intangible Assets
7,6685,8689,1776,1576,1516,172
Long-Term Deferred Tax Assets
----3.637.27
Other Long-Term Assets
1,5364,91010,36816,1058,8435,266
Total Assets
472,993373,180429,017400,929397,417400,969
Accounts Payable
9,3405,0622,36816,5307,42110,157
Accrued Expenses
-1,9072,9781,7551,7762,055
Short-Term Debt
30,000----20,000
Current Portion of Leases
324.04130.19217.6242.91444.17407.98
Current Income Taxes Payable
7.04-357.474,3123,9967,291
Other Current Liabilities
26,77628,29991,62221,76423,35821,293
Total Current Liabilities
66,44735,39897,54444,60336,99561,204
Long-Term Debt
49,39479,02478,525---
Long-Term Leases
544.38269.91644.17687.881,1141,139
Long-Term Deferred Tax Liabilities
15,35113,91710,06811,01111,2174,984
Other Long-Term Liabilities
425.12425.127,97172,78068,03062,450
Total Liabilities
132,161129,035194,752129,082117,356129,778
Common Stock
51,50736,40236,40236,40236,40233,289
Additional Paid-In Capital
98,65312,4524,8086,8007,3577,071
Retained Earnings
174,671166,822225,783258,585264,703273,253
Treasury Stock
---50,784-50,784-50,784-50,268
Comprehensive Income & Other
15,61728,00010,10312,21511,930-4,846
Total Common Equity
340,448243,676226,311263,217269,608258,499
Minority Interest
383.7469.857,9538,63010,45312,692
Shareholders' Equity
340,832244,146234,265271,847280,061271,191
Total Liabilities & Equity
472,993373,180429,017400,929397,417400,969
Total Debt
80,26379,42479,387930.791,55821,547
Net Cash (Debt)
137,28950,66771,84084,58682,71968,044
Net Cash Growth
258.43%-29.47%-15.07%2.26%21.57%91.64%
Net Cash Per Share
1846.89740.151049.461235.651208.27991.46
Filing Date Shares Outstanding
98.6668.4568.4568.4568.4562.25
Total Common Shares Outstanding
98.6668.4568.4568.4568.4568.48
Working Capital
239,468168,341156,634174,138183,101187,005
Book Value Per Share
3450.563559.673306.003845.133938.483775.04
Tangible Book Value
332,373237,401216,255256,226262,628251,500
Tangible Book Value Per Share
3368.713468.003159.103743.013836.523672.83
Land
112,939113,31492,87592,87592,87571,163
Buildings
51,99851,49951,45050,60250,60250,577
Machinery
51,88049,27648,40648,08046,34346,030
Construction In Progress
330.6311.17-76.21-52.2
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.